New immunomodulatory drugs in myeloma

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Multiple myeloma (MM) is an incurable malignancy of plasma cells. The introduction of thalidomide was a milestone in the treatment of MM. Thalidomide analogues termed immunomodulatory drugs (IMiDs) have been developed that are more effective and have less toxicity than thalidomide. The role of lenalidomide in relapsed MM has been well defined. This review discusses the data regarding the upfront use of lenalidomide with dexamethasone or in multidrug combinations, as well as its potential role as maintenance therapy. It also reviews our experience with pomalidomide, a new IMid with remarkable activity in relapsed, refractory MM.

Original languageEnglish (US)
Pages (from-to)120-125
Number of pages6
JournalCurrent Hematologic Malignancy Reports
Volume6
Issue number2
DOIs
StatePublished - Jun 1 2011

Fingerprint

Multiple Myeloma
Thalidomide
Pharmaceutical Preparations
Plasma Cells
Dexamethasone
Neoplasms
lenalidomide
Therapeutics

Keywords

  • IMiDs
  • Immunomodulatory drugs
  • Lenalidomide
  • Maintenance therapy
  • Multiple myeloma
  • Pomalidomide

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

New immunomodulatory drugs in myeloma. / Lacy, Martha.

In: Current Hematologic Malignancy Reports, Vol. 6, No. 2, 01.06.2011, p. 120-125.

Research output: Contribution to journalArticle

@article{fffb576ec3a04a24bb995c0ab1c7476a,
title = "New immunomodulatory drugs in myeloma",
abstract = "Multiple myeloma (MM) is an incurable malignancy of plasma cells. The introduction of thalidomide was a milestone in the treatment of MM. Thalidomide analogues termed immunomodulatory drugs (IMiDs) have been developed that are more effective and have less toxicity than thalidomide. The role of lenalidomide in relapsed MM has been well defined. This review discusses the data regarding the upfront use of lenalidomide with dexamethasone or in multidrug combinations, as well as its potential role as maintenance therapy. It also reviews our experience with pomalidomide, a new IMid with remarkable activity in relapsed, refractory MM.",
keywords = "IMiDs, Immunomodulatory drugs, Lenalidomide, Maintenance therapy, Multiple myeloma, Pomalidomide",
author = "Martha Lacy",
year = "2011",
month = "6",
day = "1",
doi = "10.1007/s11899-011-0077-y",
language = "English (US)",
volume = "6",
pages = "120--125",
journal = "Current Hematologic Malignancy Reports",
issn = "1558-8211",
publisher = "Springer Science + Business Media",
number = "2",

}

TY - JOUR

T1 - New immunomodulatory drugs in myeloma

AU - Lacy, Martha

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Multiple myeloma (MM) is an incurable malignancy of plasma cells. The introduction of thalidomide was a milestone in the treatment of MM. Thalidomide analogues termed immunomodulatory drugs (IMiDs) have been developed that are more effective and have less toxicity than thalidomide. The role of lenalidomide in relapsed MM has been well defined. This review discusses the data regarding the upfront use of lenalidomide with dexamethasone or in multidrug combinations, as well as its potential role as maintenance therapy. It also reviews our experience with pomalidomide, a new IMid with remarkable activity in relapsed, refractory MM.

AB - Multiple myeloma (MM) is an incurable malignancy of plasma cells. The introduction of thalidomide was a milestone in the treatment of MM. Thalidomide analogues termed immunomodulatory drugs (IMiDs) have been developed that are more effective and have less toxicity than thalidomide. The role of lenalidomide in relapsed MM has been well defined. This review discusses the data regarding the upfront use of lenalidomide with dexamethasone or in multidrug combinations, as well as its potential role as maintenance therapy. It also reviews our experience with pomalidomide, a new IMid with remarkable activity in relapsed, refractory MM.

KW - IMiDs

KW - Immunomodulatory drugs

KW - Lenalidomide

KW - Maintenance therapy

KW - Multiple myeloma

KW - Pomalidomide

UR - http://www.scopus.com/inward/record.url?scp=79957464808&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957464808&partnerID=8YFLogxK

U2 - 10.1007/s11899-011-0077-y

DO - 10.1007/s11899-011-0077-y

M3 - Article

C2 - 21327565

AN - SCOPUS:79957464808

VL - 6

SP - 120

EP - 125

JO - Current Hematologic Malignancy Reports

JF - Current Hematologic Malignancy Reports

SN - 1558-8211

IS - 2

ER -